newsfilter
← Latest News
ACCESS Newswire·

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategyOngoing generation of translational data designed to support future clinical development and deepen